Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy

被引：132

作者：

Mason, John O., III

Nixon, Peter A.

White, Milton F.

机构：

[1] Callahan Eye Fdn Hosp, Retina Consultants Alabama, Birmingham, AL 35233 USA

[2] Univ Alabama, Sch Med, Callahan Eye Fdn Hosp,Birmingham Sch Med, Dept Ophthalmol, Birmingham, AL USA

来源：

AMERICAN JOURNAL OF OPHTHALMOLOGY | 2006年 / 142卷 / 04期

关键词：

D O I：

10.1016/j.ajo.2006.04.058

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

PURPOSE: To report the use of intravitreal bevacizumab (Avastin) as an adjunctive treatment for proliferative diabetic retinopathy (PDR). DESIGN: Retrospective case review. METHODS: Institutional review board approval to review patient data was obtained for this retrospective study. Three patients underwent intravitreal injection of bevacizumab as part of their treatment for PDR after informed consent was signed. Each patient also under, went fundus photographs before the bevacizumab injection and then one to three weeks after. RESULTS: All three patients showed complete regression of their neovascularization elsewhere (NVE) and neovascularization of the disk (NVD) between one and three weeks after injection. CONCLUSIONS: The speed and degree of neovascular regression after the injection of intravitreal bevacizumab may make this procedure an important adjunctive treatment in the management of selected cases with severe PDR.

引用

页码：685 / 688

页数：4

共 6 条

[1] Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals [J].

Adamis, AP ;

Altaweel, M ;

Bressler, NM ;

Cunningham, ET ;

Davis, MD ;

Goldbaum, M ;

Gonzales, C ;

Guyer, DR ;

Katz, B ;

Patel, M .

OPHTHALMOLOGY, 2006, 113 (01) :23-28

[2]

Boyd SR, 2002, ARCH OPHTHALMOL-CHIC, V120, P1644

[3]

DAVIS MD, 2001, RETINA, P1309

[4] VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization [J].

Ishida, S ;

Usui, T ;

Yamashiro, K ;

Kaji, Y ;

Amano, S ;

Ogura, Y ;

Hida, T ;

Oguchi, Y ;

Ambati, J ;

Miller, JW ;

Gragoudas, ES ;

Ng, YS ;

D'Amore, PA ;

Shima, DT ;

Adamis, AP .

JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (03) :483-489

[5] Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration [J].

Rosenfeld, PJ ;

Moshfeghi, AA ;

Puliafito, CA .

OPHTHALMIC SURGERY LASERS & IMAGING, 2005, 36 (04) :331-335

[6] Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage [J].

Spaide, Richard F. ;

Fisher, Yale L. .

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (03) :275-278

← 1 →